Form 8-K · Current Report · Filed 2025-02-06
IQVIA Announces Fourth-Quarter and Full-Year 2024 Financial Results and Reaffirms 2025 Guidance
IQVIA Holdings Inc. reported its financial results for the fourth-quarter and full-year 2024, announcing revenue of $3,958 million for Q4 and $15,405 million for the full year. The company's GAAP Net Income was $437 million for Q4 and $1,373 million for the full year, with Adjusted EBITDA at $996 million for Q4 and $3,684 million for the full year. IQVIA also provided its full-year 2025 guidance, expecting revenue growth at constant currency ex-COVID of 4 to 7 percent, Adjusted EBITDA margin expansion of up to 20 basis points, and Adjusted Diluted Earnings per Share growth of 5 to 9 percent.
- Filer
- Iqvia Holdings Inc. IQV · NYSE
- Filed
- Accession
- 0001478242-25-000016
- CIK
- 0001478242
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$205.44
Next session
+1.3%
Since filing
+14.4%
Latest close
$235.02
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IQV reporting the same item, with the next session's move:
Exhibits (1)
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Never miss another IQV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.